GHENT, Belgium—Targeting a variety of therapeutic areas including immunology, oncology, and respiratory, biopharmaceutical company Ablynx announced a global strategic alliance with Boehringer Ingelheim to discover, develop, and commercialize up to ten Nanobody therapeutics. The collaboration will see Ablynx receive €75 million, which includes a €15-million equity investment, and the potential to receive up to €125 million per Nanobody in milestone payments, as well as undisclosed royalties.
Continue reading below...
ExplainersWhy does immunotherapy work better for some cancers than others?
A powerful tool in modern oncology, immunotherapy doesn’t work the same for everyone. Researchers are exploring why and developing ways to improve its effectiveness.
Read More"This is by far the largest financial agreement that Ablynx has signed to discover and develop innovative Nanobody therapeutics," says Dr. Edwin Moses, Ablynx CSO and chair. "We are delighted to strengthen our existing relationship with Boehringer Ingelheim by working together to develop innovative products across multiple therapeutic areas, taking full advantage of the powerful Nanobody discovery platform."
